References
- Mindham R, Lamb P, Bradley R. A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism. Br J Psychiatry. 1977;130:581–585.
- Coid J, Strang J. Mania secondary to procyclidine (“Kemadrin”) abuse. Br J Psychiatry. 1982;141:81–84.
- Jutley RS, Mason RG. Lessons to be learned: a case study approach. ‘Spontaneous’ intraperitoneal bladder rupture in a psychiatric patient–with diagnostic difficulties. J R Soc Promot Health. 2001;121(2):125–127.
- Monte AA, Hoppe J. Toxicology: anticholinergics. In: Walls R, Hockberger R, Gausche-Hill M, Walls R, Hockberger R, Gausche-Hill M, editors. Rosen's emergency medicine: concepts and clinical practice, 2-Volume Set Philadelphia (PA): Elsevier, 2017; p. 1863–1867.
- Espi Martinez F, Espi Forcen F, Shapov A, et al. Biperiden dependence: case report and literature review. Case Rep Psychiatry. 2012;(2012):949256. Available from: https://doi.org/10.1155/2012/949256
- Watkins JW, Schwarz ES, Arroyo-Plasencia AM, et al. Toxicology investigators consortium investigators on behalf of the TIC. The use of physostigmine by toxicologists in anticholinergic toxicity. J Med Toxicol. 2015;11(2):179–184.
- FDA: KEMADRIN (procyclidine hydrochloride) 5 mg Scored Tablets. Silver Spring(MD): U.S. Food and Drug Administration; 2011 July 7 [cited 2018 March 23]; [pdf webpage]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009818s018lbl.pdf.
- Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium – theory, evidence and practice. Br J Clin Pharmacol. 2016;81(3):516–524.
- Burns MJ, Linden CH, Graudins A, et al. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000;35(4):374–381.
- Teoh R, Page A, Hardern R. Physostigmine as treatment for severe CNS anticholinergic toxicity. Emerg Med J. 2001;18:412.
- Rasimas JJ, Sachdeva KK, Donovan JW. Revival of an antidote: bedside experience with physostigmine. J Am Acad Emerg Psychiatry. 2014;12:5–24.
- Arens AM, Shah, K, Al-Abri S, et al. Safety and effectiveness of physostigmine: a 10-year retrospective review. Clin Toxicol. 2018;56(2):101–107.